Physician

Sumedha Dhar, M.D

According to 2025 Medicare claims, Sumedha Dhar, M.D (NPI: 1811204266) practices nephrology in the Michigan City-La Porte, IN market, with the plurality of this provider's patient population coming from La Porte, IN. This provider's primary affiliated billing organization is DUNELAND NEPHROLOGY PC (NPI: 1598709685; TIN: 204993978) and primary practice location at 46360-0021. Dhar is affiliated with the Main Street Rural Health Cedar ACO LLC (ACO ID: A5502), participating under the MSSP model.

Dhar's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 549 traditional Medicare patients, billed 1,879 HCPCS/CPT codes, and received $151,417 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 1,315 prescription claims across 282 beneficiaries totaling $88,298 in drug costs, led by Farxiga (Dapagliflozin Propanediol). Open Payments data shows 26 records totaling $809. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have risen steadily, from $1,973 to $88,298. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	173	600	$47,494
2016	573	2,434	$188,370
2017	653	2,698	$198,631
2018	693	2,733	$262,798
2019	648	2,465	$216,869
2020	629	2,678	$225,605
2021	611	2,332	$212,222
2022	580	2,286	$194,821
2023	567	2,117	$177,108
2024	549	1,879	$151,417

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	31	64	$1,973
2016	95	515	$15,040
2017	158	982	$32,749
2018	237	1,394	$45,312
2019	206	1,321	$95,132
2020	203	1,203	$110,492
2021	214	1,075	$72,582
2022	253	1,106	$114,705
2023	250	1,220	$97,647
2024	282	1,315	$88,298

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	58	58	$129
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	117	270	$90
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	320	592	$61
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	156	625	$60
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	63	70	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Farxiga	Dapagliflozin Propanediol	31	1,770	$33,194
Sevelamer Carbonate	Sevelamer Carbonate	24	1,920	$10,170
Potassium Citrate Er	Potassium Citrate	37	2,915	$5,566
Potassium Chloride	Potassium Chloride	60	4,921	$1,855
Chlorthalidone	Chlorthalidone	56	4,990	$1,003

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	26	$809	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Sumedha Dhar, M.D?

Tedicare shows public-source Medicare data for Sumedha Dhar, M.D (NPI 1811204266), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Sumedha Dhar, M.D have ACO affiliation data?

Sumedha Dhar, M.D is shown with ACO affiliation data for Main Street Rural Health Cedar ACO LLC (MSSP, ACO ID A5502).

What billing organization is linked to Sumedha Dhar, M.D?

Sumedha Dhar, M.D is linked to DUNELAND NEPHROLOGY PC (billing NPI 1598709685) in the available physician profile data.

Does Sumedha Dhar, M.D have Open Payments data?

Sumedha Dhar, M.D has 26 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.